サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1631493

ワクチンアジュバントの市場規模、シェア、動向分析レポート：タイプ別、投与法別、用途別、地域別、セグメント予測、2025～2030年

Vaccine Adjuvants Market Size, Share & Trends Analysis Report By Type (Pathogen, Adjuvant Emulsion, Particulate), By Administration (Oral, Intradermal, Intranasal, Intramuscular), By Application, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 120 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
ワクチンアジュバントの市場規模、シェア、動向分析レポート：タイプ別、投与法別、用途別、地域別、セグメント予測、2025～2030年
出版日: 2024年12月17日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ワクチンアジュバント市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のワクチンアジュバント市場は2030年までに48億6,000万米ドルに達する見込みです。

同市場は2025～2030年にかけてCAGR 4.32％で成長すると予測されています。革新的なワクチン抗原の免疫原性が不十分であることから、ワクチン開発におけるアジュバント研究の重要性が徐々に高まっています。加えて、既存の疾患や新興疾患に対する免疫効果を長期間持続させることへの注目の高まりが、ワクチンアジュバントの需要を押し上げると予想されます。

さらに、子宮頸がんの有病率の上昇が市場を押し上げると予想されています。NCBIによると、毎年約1万5,000人の女性が子宮頸がんが原因で死亡しています。GSKのAS04アジュバント（ヒトパピローマウィルスワクチン）のように、免疫反応を長時間増強するアジュバントを開発する企業もあります。

ワクチンアジュバント市場レポートハイライト

  • ワクチンアジュバント市場は、タイプ別にアジュバント乳剤、病原体、微粒子、配合剤、その他に区分されます。粒子状セグメントが2024年に最大の市場シェアを占めました。
  • 感染症セグメントは2024年に68.0%の最大の収益シェアを占めました。この大きなシェアは、マラリア、インフルエンザ、A型肝炎、B型肝炎、C型肝炎などの感染症の流行が徐々に拡大していることに起因しています。
  • 投与セグメントは、経口、皮内、鼻腔内、筋肉内、その他に分類されます。より優れた免疫特異性により、筋肉内投与セグメントは2024年に33.8%と最大の収益シェアを占めました。
  • 北米が市場を独占し、2024年には39.4%の最大収益シェアを占めました。北米地域の市場成長要因は、新規治療の研究開発投資の増加、致死的伝染病の増加です。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ワクチンアジュバント市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場の展望
    • 関連/付随市場の展望
  • 浸透と成長の見込みマッピング
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ワクチンアジュバント市場分析ツール
    • 産業分析-ポーターのファイブフォース分析
    • PESTEL分析

第4章 ワクチンアジュバント：タイプ別、推定・動向分析

  • ワクチンアジュバント市場：主要ポイント
  • ワクチンアジュバント市場：動向と市場シェア分析、2024年と2030年
  • 病原体
    • 病原体剤市場推定・予測、2018～2030年
  • アジュバント乳剤
    • アジュバント乳剤市場推定・予測、2018～2030年
  • 微粒子
    • 微粒子市場推定・予測、2018～2030年
  • 組み合わせ
    • 組み合わせ市場推定・予測、2018～2030年
  • その他
    • その他市場推定・予測、2018～2030年

第5章 ワクチンアジュバント：用途別、推定・動向分析

  • ワクチンアジュバント市場：主要ポイント
  • ワクチンアジュバント市場：動向と市場シェア分析、2024年と2030年
  • 感染症
    • 感染症市場推定・予測、2018～2030年
  • がん
    • がん市場推定・予測、2018～2030年
  • その他
    • その他市場推定・予測、2018～2030年

第6章 ワクチンアジュバント：投与法別、推定・動向分析

  • ワクチンアジュバント市場：主要ポイント
  • ワクチンアジュバント市場：動向と市場シェア分析、2024年と2030年
  • 経口
    • 経口市場推定・予測、2018～2030年
  • 皮内
    • 皮内市場推定・予測、2018～2030年
  • 鼻腔内
    • 鼻腔内市場推定・予測、2018～2030年
  • 筋肉内
    • 筋肉内市場推定・予測、2018～2030年
  • その他
    • その他市場推定・予測、2018～2030年

第7章 ワクチンアジュバント市場：地域別、推定・動向分析

  • 地域展望
  • 地域別ワクチンアジュバント市場：主要ポイント
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • GSK
    • Novartis/CSL
    • Agenus
    • Adjuvance
    • Novavax
    • SPI Pharma
    • Invivogen
    • Avanti Polar Lipids
    • Brentagg
図表

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America Vaccine Adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 3 North America vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 4 North America vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 5 North America vaccine adjuvants market, by region, 2018 - 2030 (USD Million)
  • Table 6 U.S. vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 7 U.S. vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 8 U.S. vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 9 Canada vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 10 Canada vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 11 Canada vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 12 Mexico vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 13 Mexico vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 14 Mexico vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 15 Europe vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 16 Europe vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 17 Europe vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 18 Europe vaccine adjuvants market, by region, 2018 - 2030 (USD Million)
  • Table 19 Germany vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 20 Germany vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 21 Germany vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 22 UK vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 23 UK vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 24 UK vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 25 France vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 26 France vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 27 France vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 28 Italy vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 29 Italy vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 30 Italy vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 31 Spain vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 32 Spain vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 33 Spain vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 34 Denmark vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 35 Denmark vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 36 Denmark vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 37 Sweden vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 38 Sweden vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 39 Sweden vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 40 Norway vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 41 Norway vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 42 Norway vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific vaccine adjuvants market, by region, 2018 - 2030 (USD Million)
  • Table 47 Japan vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 48 Japan vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 49 Japan vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 50 China vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 51 China vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 52 China vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 53 India vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 54 India vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 55 India vaccine adjuvants market, by administration, (USD Million) 2018 - 2030
  • Table 56 Australia vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 57 Australia vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 58 Australia vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 59 Thailand vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 60 Thailand vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 61 Thailand vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 62 South Korea vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 63 South Korea vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 64 South Korea vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 65 Latin America vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 66 Latin America vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 67 Latin America vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 68 Latin America vaccine adjuvants market, by region, 2018 - 2030 (USD Million)
  • Table 69 Brazil vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 70 Brazil vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 71 Brazil vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 72 Argentina vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 73 Argentina vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 74 Argentina vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 75 Middle East and Africa vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 76 Middle East and Africa vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 77 Middle East and Africa vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 78 Middle East and Africa vaccine adjuvants market, by region, 2018 - 2030 (USD Million)
  • Table 79 South Africa vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 80 South Africa vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 81 South Africa vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 85 UAE vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 86 UAE vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 87 UAE vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
  • Table 88 Kuwait vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
  • Table 89 Kuwait vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
  • Table 90 Kuwait vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Vaccine adjuvants: Market outlook
  • Fig. 8 Vaccine adjuvants: Competitive insights
  • Fig. 9 Parent market outlook
  • Fig. 10 Related/ancillary market outlook
  • Fig. 11 Penetration and growth prospect mapping
  • Fig. 12 Industry value chain analysis
  • Fig. 13 Vaccine adjuvants market driver impact
  • Fig. 14 Vaccine adjuvants market restraint impact
  • Fig. 15 Vaccine adjuvants market strategic initiatives analysis
  • Fig. 16 Vaccine adjuvants market: Type movement analysis
  • Fig. 17 Vaccine adjuvants market: Type outlook and key takeaways
  • Fig. 18 Pathogen market estimates and forecasts, 2018 - 2030
  • Fig. 19 Adjuvant emulsion market estimates and forecasts, 2018 - 2030
  • Fig. 20 Particulate market estimates and forecasts, 2018 - 2030
  • Fig. 21 Combination market estimates and forecasts, 2018 - 2030
  • Fig. 22 Others market estimates and forecasts, 2018 - 2030
  • Fig. 23 Vaccine adjuvants market: Application movement analysis
  • Fig. 24 Vaccine adjuvants market: Application outlook and key takeaways
  • Fig. 25 Infectious diseases market estimates and forecasts, 2018 - 2030
  • Fig. 26 Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 27 Others market estimates and forecasts, 2018 - 2030
  • Fig. 28 Vaccine adjuvants market: Administration movement analysis
  • Fig. 29 Vaccine adjuvants market: Administration outlook and key takeaways
  • Fig. 30 Oral market estimates and forecasts, 2018 - 2030
  • Fig. 31 Intradermal market estimates and forecasts, 2018 - 2030
  • Fig. 32 Intranasal market estimates and forecasts, 2018 - 2030
  • Fig. 33 Intramuscular market estimates and forecasts, 2018 - 203
  • Fig. 34 Others market estimates and forecasts, 2018 - 2030
  • Fig. 35 Global vaccine adjuvants market: Regional movement analysis
  • Fig. 36 Global vaccine adjuvants market: Regional outlook and key takeaways
  • Fig. 37 North America market estimates and forecasts, 2018 - 2030
  • Fig. 38 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 39 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 40 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 41 Europe. market estimates and forecasts, 2018 - 2030
  • Fig. 42 UK market estimates and forecasts, 2018 - 2030
  • Fig. 43 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 44 France market estimates and forecasts, 2018 - 2030
  • Fig. 45 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 46 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 47 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 48 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 49 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 50 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 51 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 52 China market estimates and forecasts, 2018 - 2030
  • Fig. 53 India market estimates and forecasts, 2018 - 2030
  • Fig. 54 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 55 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 56 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 57 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 58 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 59 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 60 Middle East and Africa. market estimates and forecasts, 2018 - 2030
  • Fig. 61 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 62 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 63 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 64 Kuwait market estimates and forecasts, 2018 - 2030
目次
Product Code: GVR-1-68038-612-7

Vaccine Adjuvants Market Growth & Trends:

The global vaccine adjuvants market is expected to reach USD 4.86 billion by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to grow at a CAGR of 4.32% from 2025 to 2030. The significance of adjuvant research in the development of vaccines has increased gradually due to inadequate immunogenicity of innovative vaccine antigens. In addition, the growing focus on long-lasting immunization effect against existing and emerging diseases is expected to boost the demand for vaccine adjuvants.

Furthermore, rising prevalence of cervical cancer is anticipated to boost the market. According to NCBI, around 15,000 females die every year due to cervical cancer. There are certain companies developing vaccine adjuvants for this type of cancer in order to enhance the efficacy, such as AS04 adjuvant-adsorbed (human papillomavirus vaccine) by GSK, which boosts the immune response for a longer duration.

Vaccine Adjuvants Market Report Highlights:

  • The vaccine adjuvants market is segmented based on type into an adjuvant emulsion, pathogen, particulate, combination, and others. The particulate segment held the largest market share in 2024
  • The infectious diseases segment accounted for the largest revenue share of 68.0% in 2024. This large share can be attributed to the gradually growing prevalence of infectious diseases, such as malaria, influenza, hepatitis A, B, & C, and others.
  • The administration segment is categorized into oral, intradermal, intranasal, intramuscular, and others. Due to better immune specificity, the intramuscular segment accounted for the largest revenue share of 33.8% in 2024
  • North America dominated the market and accounted for the largest revenue share of 39.4% in 2024. The factors contributing to the growth of the market in the North American region are a rise in investments for R&D of new therapeutics and an increase in fatal epidemic diseases.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Type
    • 1.1.2. Application
    • 1.1.3. Administration type
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Application outlook
    • 2.2.3. Administration outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Vaccine Adjuvants Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Vaccine Adjuvants Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Vaccine Adjuvants: Type Estimates & Trend Analysis

  • 4.1. Vaccine Adjuvants Market: Key Takeaways
  • 4.2. Vaccine Adjuvants Market: Movement & Market Share Analysis, 2024 & 2030
  • 4.3. Pathogen
    • 4.3.1. Pathogen market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Adjuvant emulsion
    • 4.4.1. Adjuvant emulsion market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Particulate
    • 4.5.1. Particulate market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Combination
    • 4.6.1. Combination market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Vaccine Adjuvants: Application Estimates & Trend Analysis

  • 5.1. Vaccine Adjuvants Market: Key Takeaways
  • 5.2. Vaccine Adjuvants Market: Movement & Market Share Analysis, 2024 & 2030
  • 5.3. Infectious diseases
    • 5.3.1. Infectious diseases market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Cancer
    • 5.4.1. Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Vaccine Adjuvants: Administration Estimates & Trend Analysis

  • 6.1. Vaccine Adjuvants Market: Key Takeaways
  • 6.2. Vaccine Adjuvants Market: Movement & Market Share Analysis, 2024 & 2030
  • 6.3. Oral
    • 6.3.1. Oral market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4. Intradermal
    • 6.4.1. Intradermal market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Intranasal
    • 6.5.1. Intranasal market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Intramuscular
    • 6.6.1. Intramuscular market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Vaccine Adjuvants Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Vaccine Adjuvants Market by Region: Key Takeaways
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.3. France
      • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.6. Denmark
      • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.8. Norway
      • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.2. China
      • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.3. India
      • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.5. Thailand
      • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Market Participant Categorization
    • 8.2.1. GSK
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Novartis/CSL
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Agenus
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Adjuvance
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Novavax
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. SPI Pharma
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Invivogen
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Avanti Polar Lipids
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Brentagg
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives